Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single IV Infusion of SHR-1906 in Healthy Subjects
NCT04986540 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single IV Infusion of SHR-1906 in Healthy Subjects
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 10, 2021
- Completion date
- September 7, 2022
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.